Lupin Gets U.S. FDA Approval for Ipratropium Bromide Nasal Spray

    Synopsis:

    Lupin secured U.S. FDA approval for its Ipratropium Bromide Nasal Solution, 0.03%, a generic version of Atrovent Nasal Spray. The drug, used for rhinorrhea relief, had U.S. sales of $22 million. Lupin share price closed at ₹2,169.85, down 1.35%.


    Lupin Ltd has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Ipratropium Bromide Nasal Solution, 0.03% (21 mcg/spray). This drug is a generic equivalent of Atrovent Nasal Spray, 0.03%, originally developed by Boehringer Ingelheim Pharmaceuticals. The medication is prescribed for the symptomatic relief of rhinorrhea associated with allergic and non-allergic perennial rhinitis in individuals aged six years and older.

    Also read: Mankind Pharma Sells Mahananda to Chalet Hotels for Rs 530 Crore

    Lupin Limited

    Trade

    2415-6.19 (-0.25 %)

    Updated - 31 July 2026
    2435.00day high
    DAY HIGH
    2404.00day low
    DAY LOW
    1006308
    VOLUME (BSE)

    Key Takeaways

    • FDA Approval: Lupin gains U.S. FDA clearance for Ipratropium Bromide Nasal Solution, 0.03%.

    • Market Potential: The generic equivalent of Atrovent Nasal Spray had estimated annual sales of $22 million in the U.S.

    • Production Facility: The drug will be manufactured at Lupin’s Pithampur facility in India.

    • Financial Performance: Lupin’s Q2 net profit surged 74.4% YoY to ₹852.6 crore, while revenue grew 12.6% to ₹5,672.7 crore.

    Lupin’s Financial Growth and Market Impact

    Lupin posted robust Q2 financial results, with a net profit of ₹852.6 crore, exceeding market expectations. The revenue reached ₹5,672.7 crore, showing a 12.6% YoY increase. EBITDA surged 46% YoY to ₹1,340.4 crore, while EBITDA margins expanded to 23.6% from 18% in the prior year.

    The company’s strong operational growth reflects its strategic focus on expanding its generics portfolio. However, Lupin share price closed at ₹2,169.85 on the BSE, down by ₹29.70 or 1.35%.

    Market Overview of Ipratropium Bromide Nasal Solution

    Parameter

    Details

    Drug Name

    Ipratropium Bromide Nasal Solution

    Strength

    0.03% (21 mcg/spray)

    Equivalent to

    Atrovent Nasal Spray, 0.03%

    Indication

    Rhinorrhea relief

    Age Group

    6 years and above

    Manufacturing Facility

    Pithampur, India

    Annual U.S. Sales

    $22 million

    Lupin’s latest FDA approval strengthens its presence in the U.S. generics market. The company's financial resilience and new product launches indicate positive growth momentum. Investors are closely watching Lupin share price as it navigates market fluctuations.

    Also read: RVNL Wins South Western Railway Project Worth ₹335.4 Crore

    Do you have a trading account app or demat account app?

    You can open an account with Bajaj Broking in minutes.

    Download the Bajaj Broking app now from Play Store or App Store.

    Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

    This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

    Share this article: 

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Publish Date: 11 Feb 2025

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |